AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37166151
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D supplementation (600 mg of calcium plus 200 UI of cholecalciferol)
Trial: 37166257
Drug: Dexamethasone 0.3
RxNorm normalized name: dexamethasone 0.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.3 mg/kg
Trial: 37166385
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg at Week 0, Week 4, and every 12 weeks thereafter
Trial: 37166484
Drug: Tislelizumab +
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab + DNA hypomethylating agent (HMA) + CAG regimen
Trial: 37166675
Drug: MG Symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG Symptoms Patient-Reported Outcome (PRO)
Trial: 37166675
Drug: Quantitative MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative MG (QMG)
Trial: 37166675
Drug: MG Composite
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MG Composite (MGC)
Trial: 37166675
Drug: MG-Activities of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG-Activities of Daily Living (MG-ADL)
Trial: 37166675
Drug: MG Symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG Symptoms PRO
Trial: 37166798
Drug: Diffusing alpha-emitter
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diffusing alpha-emitter radiation therapy (DaRT) with a physical dose of 10 Gy (equivalent weighted dose of 200 CGE) to the tumor.
Trial: 37166817
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy (ET) plus trastuzumab and pertuzumab
Trial: 37166948
Drug: Memantine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine as an augmentative agent to a selective serotonin reuptake inhibitor
Trial: 37166961
Drug: Daily dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dietary self-monitoring
Trial: 37166961
Drug: Monthly dietary
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly dietary self-monitoring
Trial: 37166997
Drug: Small-molecule activator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-molecule activator of PP2A (SMAP, DT-061)
Trial: 37167165
Drug: Ergoferon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergoferon (1 tablet, 2 times a day for 3 weeks)
Trial: 37167764
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus relatlimab (NIVO + RELA; 480 mg and 160 mg, respectively)
Trial: 37167764
Drug: Nivolumab (NIVO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (NIVO; 480 mg)
Trial: 37168472
Drug: Rectal swabs
RxNorm normalized name: witch hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal swabs and molecular diagnostic tests for detection of enteropathogens
Trial: 37169401
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for 24 months
Trial: 37169499
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments for MG
Trial: 37169499
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects from treatments
Trial: 37169708
Drug: Emotion Focused
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion Focused Mindfulness Therapy (EFMT) group delivered by Zoom
Trial: 37169780
Drug: Brain serotonin
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain serotonin 4 receptor binding
Trial: 37170043
Drug: Subcutaneous opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous opioids
Trial: 37170109
Drug: Mifepristone (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (1200 mg/day)
Trial: 37170123
Drug: Open abdomen
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open abdomen (OA) management with negative peritoneal pressure therapy (NPPT) dressing
Trial: 37170191
Drug: High-dose polyethylene
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose polyethylene glycol 3350 (PEG, 459 g) and Gatorade (1.5 times the standard-dose)
Trial: 37170191
Drug: High-dose polyethylene
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose polyethylene glycol 3350 (PEG, 612 g) and Gatorade (2.0 times the standard-dose)
Trial: 37170191
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of PEG (306 g to 357 g) and Gatorade
Trial: 37170191
Drug: High-dose preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose preparations
Trial: 37170307
Drug: Adjuvant intravesical
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant intravesical instillations of the drug selected based on drug screens in patient derived organoids (PDO) - Epirubicin, Mitomycin C, Gemcitabine, or Docetaxel for 6 instillations once weekly.
Trial: 37170709
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg IFS
Trial: 37170709
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg OM
Trial: 37170833
Drug: Lowest MEEi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest MEEi tertile (MEEi<0.031 mL/s/g)
Trial: 37171081
Drug: Oral oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral oxytocin
Trial: 37171620
Drug: Rituximab, bendamustine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab, bendamustine, and low-dose cytarabine (R-BAC)
Trial: 37171721
Drug: Talazoparib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (oral, 1 mg once daily)
Trial: 37171851
Drug: Implementation intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implementation intervention including real-time and web-based training, tobacco smoking treatment protocol, expert consultation, coaching, and organizational strategy meetings.
Trial: 37172100
Drug: IMA101 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IMA101 treatment (T-cell infusion and low-dose IL2)
Trial: 37172116
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (SBP target, 110 to <130 mmHg)
Trial: 37172116
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (SBP target, 130 to <150 mmHg)
Trial: 37172200
Drug: Quadrivalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent meningococcal conjugate vaccine (one dose)
Trial: 37172204
Drug: Venetoclax-based therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax-based therapies
Trial: 37172204
Drug: Venetoclax-based treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax-based treatments
Trial: 37172934
Drug: Necessity for
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL LOTION [I KNOW Very Necessary Broad Spectrum SPF-40 Moisturizing Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necessity for analgesics
Trial: 37172969
Drug: Neoadjuvant intratumoral
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neoadjuvant intratumoral influenza vaccine treatment
Trial: 37173074
Drug: Chronic cough
RxNorm normalized name: Pediaclear Cough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic cough (CC)
Trial: 37173074
Drug: CT parameters
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT parameters and CC
Trial: 37173116
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg once daily for 7 days
Trial: 37173224
Drug: Bispecific antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific antibodies and other emerging treatment strategies
Trial: 37173291
Drug: Computerized vestibular
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized vestibular retraining therapy; 12 twice-weekly sessions.
Trial: 37173365
Drug: OBI-3424 administered
RxNorm normalized name: phentermine hydrochloride Oral Capsule [Oby-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBI-3424 administered intravenously at doses of 1, 2, 4, 6, 8, or 12 mg/m
Trial: 37173365
Drug: OBI-3424 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBI-3424 at 12 mg/m
Trial: 37173512
Drug: Intranasal esketamine
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal esketamine treatment during induction phase (twice-weekly)
Trial: 37173512
Drug: Intranasal esketamine
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal esketamine treatment during optimization/maintenance phase (individualized dosing)
Trial: 37173512
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with esketamine (up to 4.5 years)
Trial: 37173568
Drug: Active Shiatsu
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Shiatsu treatment
Trial: 37173568
Drug: Sham Shiatsu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Shiatsu treatment
Trial: 37173784
Drug: Citicoline 10
RxNorm normalized name: citicoline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline 10 mg/kg/12h IV for 4 weeks plus supportive measures
Trial: 37174643
Drug: Control (platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (platform immunotherapy)
Trial: 37174650
Drug: Probiotic formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formula containing three bifidobacteria; details on dosage and duration not provided.
Trial: 37175874
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg intravenously every 3 weeks × two doses)
Trial: 37178647
Drug: Afatinib 18
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 18 mg/m²/d
Trial: 37178647
Drug: Afatinib 23
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 23 mg/m²/d
Trial: 37178932
Drug: Semi-weekly (BIW)
RxNorm normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-weekly (BIW) focal boosted prostate SBRT delivering 35 Gy in 5 fractions with an iso-toxic boost up to 50 Gy
Trial: 37178932
Drug: Once-weekly (QW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly (QW) focal boosted prostate SBRT
Trial: 37179415
Drug: 12-week home-based
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week home-based physical activity intervention aiming to increase daily steps by 2000 from baseline
Trial: 37179458
Drug: Caregiver-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver-delivered cognitive stimulation therapy (CDCST) for 15 weeks
Trial: 37179458
Drug: Caregiver-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver-delivered cognitive stimulation therapy (CDCST)
Trial: 37179530
Drug: Multimodal mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal mechanical stimulation therapy (M-Stim) with three vibration motors (50 Hz, 100 Hz, 200 Hz) and amplitudes between 0.1-0.3 m/s for 20 minutes.
Trial: 37180485
Drug: Macadamia nuts
RxNorm normalized name: Macadamia nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macadamia nuts (~15% of daily calories) for 8 weeks
Trial: 37180505
Drug: Iptacopan 200
RxNorm normalized name: iptacopan 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iptacopan 200 mg twice daily for 24 months
Trial: 37180745
Drug: Behavioral intersectional
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intersectional stigma coping intervention (three weekly 2-h group sessions)
Trial: 37181036
Drug: Short-term rapid
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term rapid severe hypothyroidism induced by thyroid hormone withdrawal
Trial: 37181130
Drug: Puerto Rican
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerto Rican Optimized Mediterranean-like Diet (PROMED) intervention group received 1 individual nutritional counseling session on a portion-control culturally-tailored MedDiet, daily text messages for 2 months, and supplied legumes and vegetable oils.
Trial: 37181130
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received cooking utensils and one standard portion-control nutritional counseling session reinforced with daily texts for 2 months.
Trial: 37181156
Drug: High fiber
RxNorm normalized name: High Fiber Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fiber (∼38 g/d) plant-based diet
Trial: 37181420
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream as maintenance therapy after baseline therapy with topical glucocorticoids (group 1)
Trial: 37181420
Drug: Topical glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticoids without subsequent use of pimecrolimus (group 2)
Trial: 37181888
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral psilocybin (0.25 mg/kg)
Trial: 37181888
Drug: Active placebo-control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo-control agent (250 mg of niacin)
Trial: 37182434
Drug: MA (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA (160 mg orally daily)
Trial: 37182434
Drug: MA +
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MA + LNG-IUS (MA 160 mg orally daily plus LNG-IUS)
Trial: 37182534
Drug: Sulbactam-durlobactam (1·0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam-durlobactam (1·0 g of each drug in combination over 3 h every 6 h for 7-14 days)
Trial: 37182534
Drug: Colistin (2·5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin (2·5 mg/kg over 30 min every 12 h for 7-14 days)
Trial: 37182695
Drug: Maternal UIC
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal UIC ≥250 μg/L
Trial: 37182695
Drug: Maternal TSH
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal TSH ≥2.5 mIU/L
Trial: 37183098
Drug: Lidocaine hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine hydrochloride 1% i.v. at a dose of 1.5 mg/kg
Trial: 37183103
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (≤2 years since chemotherapy completion)
Trial: 37183520
Drug: Setanaxib 400
RxNorm normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setanaxib 400 mg OD
Trial: 37183520
Drug: Setanaxib 400
RxNorm normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setanaxib 400 mg BID
Trial: 37183528
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg plus chemotherapy (paclitaxel 200 mg/m2)
Trial: 37183528
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (paclitaxel 200 mg/m2)
Trial: 37183779
Drug: Brepocitinib 60
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brepocitinib 60 mg single oral dose
Trial: 37183837
Drug: PEG-rhG-CSF (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF (100 μg/kg body weight, maximum total dosage of 6 mg) administered once 24-48 hours following chemotherapy for two cycles
Trial: 37183871
Drug: 3-hydroxybutyrate (3-OHB)
RxNorm normalized name: 2-Amino-3-hydroxybutyric acid
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hydroxybutyrate (3-OHB) infusion
Trial: 37184136
Drug: Izokibep, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Izokibep, a novel IL-17A neutralizing Affibody molecule, dosage and duration not specified
Trial: 37184523
Drug: Maralixibat ≤10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat ≤10 mg/d for 14 weeks
Trial: 37184615
Drug: Group-based acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based acceptance and commitment therapy to address self-stigma
Trial: 37184839
Drug: Esmolol 14%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 14% gel with standard of care (SoC)
Trial: 37184839
Drug: Esmolol 14%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 14% gel with SoC
Trial: 37184872
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU).
Trial: 37185193
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of levothyroxine treatment after a control period of 12 weeks, with gradual discontinuation and regular monitoring of thyroid function.
Trial: 37185193
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period of 12 weeks with continuous levothyroxine treatment.
Trial: 37185197
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous remimazolam
Trial: 37185903
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention (sending glucose readings via smartphone application and monthly video calls)
Trial: 37185903
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (routine monthly on-site visits)
Trial: 37186063
Drug: Binimetinib 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib 45 mg orally twice daily (bid) with Hydroxychloroquine 400 mg orally bid
Trial: 37186094
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at incremental rates up to 1.0 μg/kg/min
Trial: 37186094
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of phenylephrine infusion
Trial: 37186265
Drug: Intranasal GnRH-agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal GnRH-agonist
Trial: 37186357
Drug: Transabdominal electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transabdominal electrical stimulation by interferential therapy (IFT)
Trial: 37187198
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (3 mg/m2)
Trial: 37187198
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (idarubicin, cytarabine, etoposide, ATRA)
Trial: 37187201
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy
Trial: 37187863
Drug: e-CBT (online
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-CBT (online cognitive behavioral therapy)
Trial: 37187878
Drug: Leucine-enriched amino
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-enriched amino acid supplementation (6 g per day for 12 weeks)